Contineum Therapeutics, Inc. (CTNM) fundamentals score
Contineum Therapeutics is a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. It targets biological pathways associated with specific clinical impairments that it believes, onces modulated, will demonstrably alter the course of disease.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.1 out of 10, Weak long-term fundamentals
- Growth: 2.3/10
- Profitability: 1.0/10
- Financial health: 7.7/10
- Earnings quality: 10.0/10
- Valuation: 1.5/10
Scores are calculated from Contineum Therapeutics, Inc.’s SEC filings, using the 12 months through 2024-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10